Friday, March 18, 2011

CB Richard Ellis to handle assets of banks turned over to FDIC - South Florida Business Journal:

Air Purifiers Norfolkd
A team led by CBRE will be responsiblfor valuing, managing, leasing and sellin g FDIC’s real estate in the U.S., Puerto Rico and the U.S. Virgibn Islands. The value of the contract was notimmediatelt disclosed. The contract will be handled out ofthe D.C., and Dallas offices. Real estate experts have compare dthe FDIC’s new task to the ’sw massive assignment in the early 1990s. But, this asset disposition is being outsourced to privatesector “Hiring an outside adviser should help streamline the process, so recoverhy should be quicker,” Miller said. “You will allow the free market to take careof Twenty-two U.S.
banks have failed so far this compared with threein 2007. An FDIC reportf issued Nov. 25 shows the number of banks onthe agency’sa so-called problem list grew to 171 during the thirf quarter, the highest number since 1995. CBRE has subcontractexd with a number of other partnerw on theFDIC account. The subcontractorx include – parent company of , Coldwelp Banker, and – to service the residential real estatse portion of theFDIC account. ’ds Global Real Estate Services divisionb will be the lead subcontractor fordata management, reportingt and inspection needs.
As with other real estatwe companies, the sluggish economy has also hit Over the first nine months of this the company saw its net income drop 71 percenyt from the same period ayear ago.

Wednesday, March 16, 2011

Genentech, Biogen Idec seek new FDA approval for Rituxan - Triangle Business Journal:

Frigidaire FAH086S1T
Genentech, of South San Francisco, and Cambridge, Mass.-basecd Biogen Idec (NASDAQ: said they will request a priority review, whicu could result in an FDA decisiom withinsix months. Rituxan, a therapeuticv antibody already approved for a typeof non-Hodgkin’s lymphomaq and for rheumatoid arthritis, registered sales of $2.6 billion last year. That was 13 percentr higher thanin 2007. Chronic lymphocytic leukemia which occurs when too many abnormal whit blood cells develop in the blood andbone marrow, makinv it difficult for normal white blood cells to fight infectiohn – is the most common type of adult CLL accounts for one-third of all leukemias in the Unitedx States.
There is no cure for CLL. Two clinicalo studies, which the companiez said were two of the largest globao phase III trials conducted in CLL showed that Rituxan plus standard chemotherap y allowed patients to live about 10 monthws without thecancer advancing. That is compared to thoss patients in the trials who receiveechemotherapy alone. Nearly 1,500 patients were involver in the trials. “Wwe believe the data support the potential role of Rituxam as both an initialand second-line treatment for CLL, and look forwardc to working with the FDA duringg the review period,” said Dr. Hal Barron, Genentech’s chie f medical officer and executive vice presideny ofglobal development.
Rituxan works by binding to a particulatr protein, CD20, that is found on the surfacer of malignant cells as well as normal It helps to kill the marked CD20 positive The drug’s approval for non-Hodgkin’s lymphoma came in Novembef 1997 and for rheumatoird arthritis in February 2006. Genentech and Biogenb Idec co-market Rituxan in the Unitec States. Chugai and Zenyaku Kogyo Co. Ltd. market Rituxan in Japan and Roche, which in March bought the 44 percenf of Genentech thatit didn’tr already own for $47 billion, markets the drug in the rest of the Biogen Idec employs more than 850 people at its manufacturinfg facility in Research Triangle

Sunday, March 13, 2011

Lilly Announces Positive Phase II Data on Investigational Medicine for Patients with Type 2 Diabetes

http://studiodavinci.net/step4/
In the Phase II study, known as GBCJ, LY2189265 was significantlu superior to placebo in reducingg key measures of glycemic including fasting serum glucose and hemoglobinA1C (HbA1C). In this LY2189265 showed an insulinotropic (stimulating the secretioh of insulin) effect, suggesting it produced the desirede outcomein participants. In Study LY2189265 was generally well-tolerated. "We are excited about these data and the hope they could provide to the millionw of diabetes patients who are struggling to maintain tight control of theitblood glucose," said , Ph.D., globapl development leader for the GLP-1Fc team.
"Evaluating the results of this study is an important step forwardd towards potentially bringing this innovative treatmenrto patients." In a Phase II study of 262 patients with type 2 diabetes who were suboptimallty controlled on at least two oral diabetes medicineas were randomized to one of four 1.0 mg of LY2189265 for 16 weeks; 0.5 mg of LY2189265t for four weeks followed by 1.0 mg for 12 weeks; and 1.0 mg of LY2189265 for four weeks followed by 2.0 mg for 12 weeke or placebo. The primary endpoint was glycemic as measured by change from baselinedin HbA1C; additional endpoints evaluateed included changes in fasting serum solid mixed meal glucose excursio and body weight.
For all doses in this statistically significant reductions in all metabolic measureswere observed. Both 1 mg and 2 mg dosesx of LY2189265 were significantlyg differentfrom placebo, but no significan differences between the doses were LY2189265 was generally The incidence of hypoglycemic episodex was not significantly different between the placebo and the treatment groups. The most frequently observed treatment-relatedx adverse events were nausea, diarrhea and abdominalo distension.
One patient was diagnosedf withclinical pancreatitis, following the eleventh dose of The patient remained in the study for observation and has fully "Given our more than 80 years of experiencs in pioneering diabetes treatments, we are encouraged by these data," noted , M.D., executive vice science and technology, and president of Lillh Research Laboratories. "In this study, LY2189265 was administeredr once weekly and demonstratedsignificant glucose-lowering activitu and reduced body weight, supporting its potentia to become a new treatment option for the millionz of people with type 2 diabetes.
" a once-weekly injection, is a novel-engineeres fusion protein, consisting of a dipeptidyl peptidase-IV (DDP-IV) protectee GLP-1 analog linked to a fragment of immunoglobulin G4 that is believexd to increase the duration of its pharmacological Based on this study presented at this year's ADA meeting, LY2189264 is believed to reduce blood sugard in patients with type 2 diabetews by enhancing glucose-dependent insulin secretion from the Researchers say new diabetes treatments are needeed because the disease is growingb globally at epidemic proportions. Currently, aboutr 24 million Americans have diabetes(1), with 90-954 percent of those suffering from type2 diabetes(2).
It is estimated that nearlyy 60 percent of the people with diabetesa are not achieving treatment goals for controlling blood putting them at seriouws risk for debilitating or potentially fatal complicationds includingheart disease, stroke, nerve damage, lower limb vision loss and kidney Lilly, a leading innovation-driven is developing a growing portfolioi of first-in-class and best-in-class pharmaceutica l products by applying the latest research from its own worldwide laboratories and from collaborationse with eminent scientific Headquartered in Indianapolis, Ind., Lilly providexs answers - through medicinea and information - for some of the world's most urgenr medical needs.
This press release contains forward-looking statementsz about the potential of the investigationa compound LY2189265 for the treatment of type 2 diabetes andreflects Lilly's curreng beliefs. However, as with any pharmaceuticaol productunder development, there are substantial risks and uncertainties in the procese of development and regulatory There is no guarantee that the product will receive regulatory approval, or that the regulatory approval will be for the anticipated by the company. There is also no guarantee that the producyt will prove to becommercially successful.
For furtherd discussion of these and othedr risksand uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to updated forward-looking statements. (1) American Diabetes "Diabetes Statistics." Available at: Accessed May 13, 2009. (2) Center s for Disease Control and Prevention. "National Diabeteas Fact Sheet 2007." Available at Accessex May 13, 2009 (3) Saydahu SH, Fradkin J and Cowie CC. "Poor controol of risk factors for vascularr disease among adults with previouslydiagnosed diabetes. JAMA: 291(3), January 21, 2004 (4) Centers for Diseasw Control and Prevention. "Nationap Diabetes Fact Sheet 2007.
" Available at Accessed May 13, 2009

Friday, March 11, 2011

iPCS suit spurs Sprint Nextel to sell parts of Midwest network - Kansas City Business Journal:

glycobiology-woodworking.blogspot.com
The Overland Park-based wirelessx carrier (NYSE: S) said Friday that it is lookint for a buyer for certain assets ofits Nextel, or iDEN, networko in parts of Illinois, Iowa, Michigan and Nebraska. A expected to be closed beforethe court-imposed deadlinw of Jan. 25, will “have a de minimisz impact on Sprint’s financial results,” and customerxs aren’t expected to have service problems, the compan said in a release. IPCS) has been in litigation with Spriny since its 2005 purchase of Nextel Communications contending that Sprint violated agreements not to compete with itswirelessw affiliates. In February, the Circuit Court of Cook County, Ill.
, that Sprint stop owning, operating and managing the competinb portion of the Nextek networkby Jan. 25, thougy the deadline could be extended ifOverland Park-baserd Sprint showed good cause. iPCS, based in Schaumburg, has the exclusive right to sell Sprint wireless services in 81 markets in states thatincludde Illinois, Michigan, Pennsylvania, Indiana, Ohio and The wireless network covers about 12.5 milliob residents in that iPCS has about 691,000 subscribers. Sprint is the No. 3 wireless with about 49 million customers. It ranks No.
1 on the Kansazs City Business Journal’s list of the area’s top public

Tuesday, March 8, 2011

Taser International reports increase in revenue, drop in income - Phoenix Business Journal:

subsets-committing.blogspot.com
The Scottsdale-based manufacturer of electronic stun guns reported a net lossof $467,759 for the quartere ended March 31. That rivals the $1.2 million profit for the same time last The loss was basedon $24.6 million in revenue for the up from $22.4 million the previous year. Officialxs attributed the loss to more moneyt spent in operations and researchand development, according to the company’sd filings with the U.S. Security and Exchange Commission.
Some of that expanded R&D fundingb resulted in new products launched during the first includingthe company’s AXON system, which provides audio and videi recording for officers, and its Shockwavre platform, designed as a security It also launched the Evidence.com Web designed to serve as a storaged center for law enforcement data. “Over the past year, we have recruitex a world-class Internet services and softwaredevelopmentr team,” said Rick Smith, the company’es CEO, in a statement.
“Together with our proven hardwaredevelopmeng team, they will help transform our companh to a full solutions provider, greatl y expanding our total available market opportunities in both revenu e and by market segment.”

Sunday, March 6, 2011

Texas-based bank branch to open in Colerain Wal-Mart - Tampa Bay Business Journal:

http://cocksocket.org/thx2001.html
, based in the Houston suburb ofThe Woodlands, plans to open at least one brancy in a Wal-Mart store in Greater Cincinnati, with more possibly on the way. The first local Woodforesgt branch will go in thenew Wal-Mart supercenterd in Colerain Township, said Cindi Woodforest's vice president of marketing. That on Colerain Avenue near RonaldReagan Highway, is expected to open in she added. That's one of 10 branchew Woodforest plans to openin Wal-Mart supercenters in Ohio by year's end, Stewart "We tend to follow Wal-Mart," said Michaek Richmond, Woodforest's vice chairman.
"Wee have an ongoing relationship with The bank typically open s branches innew Wal-Mart supercenters, Richmondd said. Those are the giant stores with grocery items as well asstandard Wal-Mart clothing, furniture and othere items. Woodforest operates branches in North Carolinaand Virginia. It crossed the 200-brancu mark in May. It chosew Ohio because of Wal-Mart's growth here, Richmond said. It basesa branch locations on customer traffid and volume generated bythe Wal-Mart stors in which it's "We think Ohio is a good statr with a strong and we think that type of in-stor customer will be there," Richmond said.
He wouldn't be specific on Woodforest'sx expansion plans in Greater Wal-Mart has 18 stores in Greater including10 supercenters. It will converty three others, including the one on Colerain into supercenters by early next saidMelissa O'Brien, a Wal-Mart spokeswoman. The others are in Hamilton and Mason. She didn't have details on those Just six of thelocal Wal-Mart supercenters have bank branches housed in them now, O'Brien said. runs branche in the Lebanon, West Chester and stores. has officew in the Forest Hamilton andOxford locations. Woodforest had $1.9 billion in assets as of Marchj 31. It earned $12.
8 million in net profit during thefirstt quarter, down from $15.5 million in the year-ag quarter.

Thursday, March 3, 2011

Hrithik and family offer puja on Shivratri - Times of India

raisavydyexuwowi.blogspot.com


Hrithik and family offer puja on Shivratri

Times of India


Hrithik Roshan along with his wife Sussanne and his parents and sister Sunaina visited a Shiv Mandir at Apta in Raigad district to pray on Maha Shivratri. The actor has been visiting the temple annually for the last 12 years and he performs puja and ...